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Fructose 1,6-bisphosphatase (FBPase) is a key enzyme in gluconeogenesis. It is a potential
drug target in the treatment of type II diabetes. The protein is also associated with a rare
inherited metabolic disease and some cancer cells lack FBPase activity which promotes
glycolysis facilitating the Warburg effect. Thus, there is interest in both inhibiting the en-
zyme (for diabetes treatment) and restoring its activity (in relevant cancers). The mammalian
enzyme is tetrameric, competitively inhibited by Fructose 2,6-bisphosphate and negatively
allosterically regulated by AMP. This allosteric regulation requires information transmission
between the AMP binding site and the active site of the enzyme. A recent paper by Topaz
et al. (Bioscience Reports (2019) 39, pii:BSR20180960) has added additional detail to our
understanding of this information transmission process. Two residues in the AMP binding
site (Lys112 and Tyr113) were shown to be involved in initiating the message between the two
sites. This tyrosine residue has recently be shown to be important with protein’s interac-
tion with the antidiabetic drug metformin. A variant designed to increase metal ion affinity
(M248D) resulted in a five-fold increase in enzymatic activity. Interestingly alterations of two
residues at the subunit interfaces (Tyr164 andMet177) resulted in increased responsiveness to
AMP. Overall, these findings may have implications in the design of novel FBPase inhibitors
or activators.
Fructose 1,6-bisphosphatase and disease
Fructose 1,6-bisphosphatase (fructose diphosphatase; FBPase; EC 3.3.1.11) catalyses the hydrolysis of
fructose 1,6-bisphosphate to fructose 6-phosphate [1,2]. This reaction occurs in gluconeogenesis and in
the Calvin cycle. In gluconeogenesis, it is one of three reactions which are not the exact reverse of the
corresponding reaction in glycolysis. While ATP is required to phosphorylate fructose 6-phosphate in
glycolysis, none is produced by the dephosphorylation in gluconeogenesis. The enzyme also serves as a
key regulatory point, being inhibited by AMP and fructose 2,6-bisphosphate [3,4]. In contrast, the en-
zyme performing reverse reaction at this point in the glycolytic pathway, phosphofructokinase (PFK; EC
2.7.1.11) is activated by both AMP and fructose 2,6-bisphosphate [5–7]. The consequence of this is that,
under conditions of low cellular ATP concentrations, FBPase is relatively inactive compared with PFK and
ATP synthesis is stimulated. This avoids a ‘futile cycle’ in which fructose 1,6-bisphosphate is generated
and hydrolysed, consuming ATP for no metabolic purpose [8].
FBPase is a homotetramer in most species studied to date, with yeasts being a notable exception [9,10].
Like many oligomeric enzymes it exhibits allosteric behaviour. Fructose 2,6-bisphosphate inhibition is
competitive, with the compound binding to the active site and sterically hindering access by the substrate,
fructose 1,6-bisphosphate [4]. In contrast, AMP binds at a separate site, distant from the active site. Its
binding promotes a conformational change in the tetramer in which two subunits rotate by approximately
19◦ relative to the other two resulting in a less active form of the enzyme [11]. These two ligands do not
act independently and there is known to be synergy between them: fructose-2,6-bisphosphate binding
reduces the concentration of AMP required for a given level of inhibition [3,12]. It also induces positive
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co-operativity in the kinetics of the forward reaction, converting a hyperbolic (Michaelis–Menten) relationship be-
tween substrate concentration and rate into a sigmoidal one [3].
FBPase inhibition has been suggested as a potential therapy for type II diabetes [13,14]. In this disease, gluconeo-
genesis is a significant contributor to excess glucose. Reducing this excess would mitigate pathology related to high
glucose concentrations in the blood and tissues. FBPase is an attractive target since its inhibition would only affect
gluconeogenesis and not glycolysis. Furthermore, the existence of natural allosteric regulation of the enzyme suggests
that it may be possible to mimic the effect of AMP, dramatically reducing its activity. Thus drug discovery efforts have
focused on identifyingmolecules which recognise the AMP binding site, induce allosteric inhibition of FBPase but do
not interact with other adenosine nucleotide binding enzymes. Some of these have demonstrated antidiabetic prop-
erties in cell and animal models [15–26]. Recently, the widely used type II diabetes drug, metformin, has been shown
to act (at least in part) through the inhibition of FBPase, most likely by interaction at the AMP binding site [27].
FBPase is associated with a rare, autosomal recessive inherited metabolic disease (OMIM #229700). The incidence
is estimated to be between 1/900000 and 1/350000 in European populations [28]. Disease-associated mutations in-
clude frameshifts, deletions, splice donor variants, andmissensemutations. Relatively little work has been done on the
consequences of the missense mutations on the enzymatic activity or stability of FBPase. Some variants (e.g. p.G164S,
p.A177D and p.G261A) are inactive when expressed as recombinant proteins, suggesting that these point mutations
result in significant changes to protein structure and/or folding [29,30]. Patients suffer from impaired gluconeogen-
esis and, consequently, hypoglycaemia, ketosis and lactic acidosis [31]. If left untreated, this can be fatal in newborn
babies. However, if diagnosed early, interventions can bemade which result in a good prognosis. These include avoid-
ance of fasting, enrichment of the diet with glucose, and the reduction in fructose (and precursors such as sucrose)
in the diet [32].
In clear cell renal cell carcinoma (ccRCC; the most common form of kidney cancer), cells lack FBPase activity,
due to a chromosomal deletion [33]. Complementation of ccRCC cells with the wild-type FBPase gene inhibits their
growth [33]. Thus lack of FBPase activity is necessary for the survival of these cells. Reduced FBPase activity has
also been observed in some other forms of cancer cells (e.g. gastric, liver and cervical cancer) [34–36]. This effect is
believed to be due to two factors. First, the loss of FBPase activity blocks gluconeogenesis and stimulates glycolysis
[33]. Cancer cells typically rely heavily on glycolysis as a source of ATP and glycolytic intermediates, precursors of
building blocks for synthetic reactions, even in aerobic conditions (the Warburg effect). Second, FBPase interacts
with, and inhibits the activity of, hypoxia-inducible factors (HIFs). This inhibition promotes aerobic metabolism and
restrains cell proliferation. Its loss results in a second factor which up-regulates the glycolytic pathway and removes a
block on cell proliferation [33].
Getting the message across
The existence of allostery in FBPase infers the presence of information transmission pathways within the protein.
Typically, allosteric changes are transmitted through proteins by conformational changes, alterations in mobility or
a combination of the two [37]. Crystal structures of FBPase with and without AMP bound have provided consider-
able information on the changes which occur at the ligand binding site and at the interface between subunits of the
tetramer [11,38–40]. These structural studies have been complemented by site-directed mutagenesis work which has
investigated hypotheses about the role of individual amino acid residues in mediating the conformational changes
which accompany AMP binding [41–43]. Molecular dynamics simulations have been used to predict changes to mo-
bility which occur as part of this conformational change. One consequence of these structural and dynamic changes
is the displacement of a loop in the active site. This loop is critical for catalysis and its movement away from the
substrate binding site renders the enzyme less active [44].
Recent work by Topaz et al. [45], published in Bioscience Reports extends our understanding of infor-
mation transmission in mammalian FBPase. This study focused on seven variants: two which alter residues
in a previously identified allosteric communication pathway and binding site for the allosteric inhibitor
(4-(3-(6,7-diethoxy-quinazolin-4-ylamino)-phenyl)-thiazol-2-yl)-methanol (PFE; L56A and L73A); two affecting
residues at the subunit interface (Y164A and M177A); two altering residues in the AMP binding site (K112A and
Y113A) and one which changes a residue in a metal ion binding site (M248D).
As expected, alteration of the two lysine residues in the AMP binding site resulted in a lower responsiveness to
regulation by this compound, but did not affect regulation by fructose 2,6-bisphosphate. The positively co-operative
response to AMP was abolished by these changes. These variants also had increased catalytic efficiency (as measured
by the specificity constant kcat/Km).AY113F variant (Y114F in the numbering schemeused in the paper reporting this
variant) has been recently reported to have greatly reduced sensitivity to AMP, but also to fructose 2,6-bisphosphate,
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suggesting that this is a critical region in the AMP binding site [27]. It appears that these residues are not just involved
in the binding of AMP, but also in the initiation of information transmission to the active site.
Interestingly, the two variants located at the subunit interface resulted in a slight increase in responsiveness to both
AMP and fructose 2,6-bisphosphate. Overall, they are less enzymatically active, but retain positive co-operativity to-
wards AMP. The two variants in the allosteric communication pathway had little effect on AMP responsiveness or
catalytic efficiency and a small effect on fructose 2,6-bisphosphate responsiveness. These are an interesting set of
results since these changes might have been expected to disrupt communication. That they (largely) did not do so
suggests the possibility of alternative information transmission pathways. Alternatively, it is possible that the alter-
ations to these residues are not sufficient to fully disrupt the transmission of information. This may be particularly
the case if protein mobility, as well as conformational changes, is important in mediating the allosteric effects. Such
alterations are often critical in the transmission of information within proteins [37,46,47]. Further molecular dynam-
ics simulations to understand the mobility of FBPase may yield a greater understanding of this aspect of information
transmission.
While all the alterations of residues to alanine were designed to abolish interactions within the protein or between
the protein and its ligands, the M248D variant was intended to increase the affinity for divalent metal ions. This
variant has an impressive (greater than five-fold) increase in catalytic efficiency combinedwith a substantially reduced
responsiveness to fructose 2,6-bisphosphate. As predicted, its affinity formagnesium is increased (six-fold, compared
with the wild-type). Thus, the authors’ prediction that engineering FBPase to bind more tightly to the metal ion will
result in increased activity was vindicated. Increases in catalytic efficiency and turnover are relatively rare outcomes
of enzyme engineering experiments. In general, most changes reduce substrate affinities, turnover and efficiency
[48]. The approach adopted here of increasing metal ion affinity is one which could, potentially, be adopted in other
systems including those of biotechnological interest.
Conclusion: implications for disease and treatment
While these experiments shed new light on the molecular mechanisms of information transmission in mammalian
FBPase, the story is not complete. A map of the changes resulting from AMP binding and how these affect catalysis
is not yet available. Nevertheless, each new set of data on FBPase variants which affect the process increases the
knowledge base which can be exploited in the design of new inhibitors. The discovery that metformin targets this
enzyme also strongly supports the proposition that new FBPase inhibitors may have potential as antidiabetic agents.
Understanding these communication pathways between two separated sites (the AMP binding and the active site)
in the regulation of the enzyme’s overall activity may also be important in determining the molecular changes which
underpin FBPase deficiency. It is possible that some point mutations may affect this allosteric regulation, rather than
the activity, of the enzyme. In cancers where lack of FBPase activity contributes to tumour progression, there may
be a case for introducing the protein using strategies similar to those employed in enzyme replacement therapy for
inheritedmetabolic diseases. Ideally, the protein usedwould be engineered for increased stability, activity andhalf-life.
The M248D variant may be useful in this context. Finally, many enzymes exhibit allostery and insights gained in
relatively well-characterised systems such as FBPasemaywell have applications inmore poorly characterised or newly
discovered enzymes.
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